Article
Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer.
Pharmacogenetics and genomics - 1 Jul 2007
Jaremko Malgorzata, Justenhoven Christina, Schroth Werner, Abraham Benny K, Fritz Peter, Vollmert Caren, Illig Thomas, Simon Wolfgang, Schwab Matthias, Brauch Hiltrud
Abstract excerpt
OBJECTIVES: Outcome and survival in anthracycline-based and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of invasive breast cancer are unpredictable. Insights into treatment prediction are expected from studies searching for an association between genetic polymorphisms and trea...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.